Notably, activated T cells and hematopoietic stem cells show low CCR1 expression, at levels even lower than those observed for established MM targets, like BCMA, suggesting its potential to selectively target MM cells while sparing healthy tissues. Here, CCR1 is linked to Miyoshi myopathy.